Sanofi invests in the future of mRNA with plan to pump billions of dollars into next-gen cell therapy business

Kyle Blankenship

With Moderna and Pfizer/BioNTech paving the road for mRNA therapeutics, a gold rush is underway across biopharma to take that promising baton and run with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi invests in the future of mRNA with plan to pump billions of dollars into next-gen cell therapy business

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

Where the money is: The top 100 venture investors in biotech

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

How AI can address ongoing challenges in the life sciences industry

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sanofi invests in the future of mRNA with plan to pump billions of dollars into next-gen cell therapy business